Business Context and Reporting Period
Company: Cryomedical Sciences, Inc. (Note: Input metadata referenced "Biolife Solutions Inc," but the filing text identifies the registrant as Cryomedical Sciences, Inc.)
Reporting Period: Quarterly period ended June 29, 1997 (Six months ended June 29, 1997).
Business Overview: The Company researches, develops, manufactures, and markets cryosurgical systems, primarily the "AccuProbe" family of devices. Products are cleared for use in dermatology, general surgery, neurosurgery, and urology. In March 1997, the Company received FDA clearance for the AccuProbe 600 series and submitted an application for the Cryo-lite(R) hand-held products.
Key Financial Metrics
| Metric | Six Months Ended June 29, 1997 | Six Months Ended June 30, 1996 |
|---|---|---|
| Sales & Other Revenues | $1,847,310 | $3,161,800 |
| Gross Profit | $842,124 (46% margin) | $1,037,354 (33% margin) |
| Net Loss | $(727,791) | $(2,400,750) |
| Net Loss Per Share | $(0.02) | $(0.09) |
| Cash and Cash Equivalents (End of Period) | $773,931 | $1,250,871 |
| Working Capital | $2,323,088 | $3,164,304 |
| Net Cash Used in Operating Activities | $(868,699) | $1,658,270 (Provided) |
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 42% year-over-year to $1.85 million. Management attributes this to a decline in AccuProbe system sales and fewer procedures performed due to a lack of formal Medicare reimbursement for urologic cryosurgery.
- Improved Margins: Despite lower revenue, gross profit margin improved from 33% to 46% due to a favorable change in product sales mix and continued cost reduction measures.
- Expense Reduction: Operating expenses decreased significantly. Research and development dropped 24%, sales and marketing dropped 62%, and general and administrative expenses dropped 60%, primarily due to headcount reductions.
- Cash Flow Reversal: The Company shifted from generating $1.66 million in operating cash flow in the prior year to using $869,000 in the current period, driven by the net loss and changes in working capital.
Outlook, Risks, and Contingencies
Management Commentary and Guidance
Management expects sales for the remainder of 1997 to be lower than comparable prior-year periods. The Company believes its current cash and working capital are sufficient to fund operations for the next 12 months, contingent on sales levels and continued expenditure reductions. The Company may pursue short-term financing or additional equity financing if necessary.
Material Risks and Contingencies
- Reimbursement Uncertainty: Sales are heavily constrained by the lack of national Medicare coverage guidelines for urological cryosurgery. The Health Care Financing Administration (HCFA) is considering a noncoverage policy pending a clinical study.
- Legal Proceedings (Plaintiff): The Company sued EndoCare, Inc. and Dr. ZhoaHua Chang for trade secret misappropriation and breach of contract. A preliminary injunction was issued against Dr. Chang in July 1997. The Company seeks $10 million in compensatory and $20 million in punitive damages.
- Legal Proceedings (Defendant): Vendor Concept Group, Inc. sued the Company for approximately $3 million, alleging breach of a development agreement and theft of proprietary information. The Company denies liability and intends to defend vigorously.
Investor Verification Checklist
- Verify the status of the HCFA clinical study and potential impact on Medicare reimbursement for urological cryosurgery.
- Monitor the progress of the lawsuit against EndoCare, Inc. and the potential for damages recovery.
- Assess the defense strategy and potential liability exposure regarding the Concept Group, Inc. lawsuit.
- Confirm the Company's ability to maintain liquidity without additional equity financing given the cash burn rate.
- Review the adoption and market reception of the new AccuProbe 600 series and Cryo-lite(R) products.